Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.
about
Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon systemPentosan polysulfate: a novel therapy for the mucopolysaccharidosesAnti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VIThe effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade.Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidosesCurrent and emerging treatments and surgical interventions for Morquio A syndrome: a reviewUpregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression.Mucopolysaccharidosis VI.Bone density assessment in patients with mucopolysaccharidosis: A preliminary report from patients with MPS II and VI.Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.Orthopedic management of the extremities in patients with Morquio A syndrome.Acid ceramidase maintains the chondrogenic phenotype of expanded primary chondrocytes and improves the chondrogenic differentiation of bone marrow-derived mesenchymal stem cellsOrthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey.The effect of Tlr4 and/or C3 deficiency and of neonatal gene therapy on skeletal disease in mucopolysaccharidosis VII mice.Ultrasonographic Features of Hip Joints in Mucopolysaccharidoses Type I and II.Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation.Excessive activity of cathepsin K is associated with cartilage defects in a zebrafish model of mucolipidosis II.Gene therapy for lysosomal storage diseases (LSDs) in large animal models.Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII.C-Type Lectin Receptor Dectin-2 Binds to an Endogenous Protein β-Glucuronidase on Dendritic CellsLong circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model.Differential expression of matrix metalloproteinases in the serum of patients with mucopolysaccharidoses.Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands.Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantation.Pathogenesis of mitral valve disease in mucopolysaccharidosis VII dogs.Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure.Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis.Mechanism of shortened bones in mucopolysaccharidosis VIIThe effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and IILong-term nonsense suppression therapy moderates MPS I-H disease progression.Carotid intima-media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlates with arterial stiffness.Mucopolysaccharidosis IVA and glycosaminoglycans.Regenerative potential of glycosaminoglycans for skin and bone.Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.Extracellular matrix components: an intricate network of possible biomarkers for lysosomal storage disorders?Mucopolysaccharidoses.
P2860
Q24631198-322F88FB-24FD-4F1B-9BAE-B127EFB0CB9AQ27319509-79983DC3-037D-4AC8-BAB5-ABBA76E562B2Q28476636-97802056-014B-4C40-B52B-1127DEFBB63AQ30540876-8ECADB02-7668-44F3-B158-8EA3FE9A5B02Q33579453-2A6C2EBA-811F-41DE-B5C0-CE8910D98D6CQ33591661-5AC92A94-E75E-4D82-8A0F-08266B0EB9DCQ33610398-DAEBE786-88B0-471F-946A-5A6332081C06Q33729335-79202FA4-0911-47F7-9FA6-2266C1A35B2CQ33863356-9A264D51-FB2B-4393-B0D5-BD3ACC6690CAQ33966273-4D6184CE-6EF1-4B88-9758-524D13FC16F5Q33995906-7657301A-AD36-45ED-8E2F-977B326FD9E4Q34005906-7AD9217B-F07C-44F3-A403-4D261387DAABQ34028791-B7FD00F1-8B1B-4225-9660-839D0137C832Q34701981-1423C671-5B54-481D-A125-35B8E0551D86Q35128899-E1EAF458-0599-49CD-92A7-9A9B1C440C39Q35237967-8DDCCFF5-5EE0-440D-A5F2-C3322D1E80E8Q35553148-9412EBDE-0C62-4E41-8A92-C68AC88DEB8FQ35767677-24C39DCC-96E7-48E5-9956-9B61823D7255Q35794555-CEB8301E-313F-44D8-B56D-762D99BCC1FEQ35923476-D9122B93-AB58-403B-9A15-560B922CAAD3Q36190865-9E45BC0A-38F3-44B7-B171-19C08618F2A7Q36238416-EA33AC11-B2EB-4BBC-9A38-462E29ECF7F3Q36240723-5868C402-7DC1-49A1-BE2B-06A4014E9263Q36433328-D12252CF-22BE-4916-9AF2-4A309DB52FAEQ37017526-AD9499C2-F9F7-4C57-AE30-981C0DA11D6DQ37080149-DB80C5D0-270E-4889-8967-F1441E5EA4C6Q37238697-126D4C6F-4B2C-45F0-8F5B-9371D8C82E9AQ37366102-43B59409-8AB9-473A-83B4-7B813C49C736Q37413691-1369B685-6AE1-411C-BDB9-B86998193F63Q37415918-1A0743F2-F1B1-49F9-B065-4E0CBDB12981Q37416992-70DA5989-840B-4D8F-8E72-C82D039D9124Q37472945-6E2ED3C9-041F-4982-B4DF-36E42B020FE6Q37587862-E07B6A76-39A6-4906-883D-6141B24EC41DQ37619694-BC2C75FD-C67C-4698-9A64-9363B7CEDBF0Q37624919-F61DB0A0-BA70-4AC4-A740-F309738FA66CQ37626886-DB83F0B7-07A5-4E2F-B80B-CDE5FA57508BQ37970313-48F913D7-5AEC-4388-B4C5-D4EC3FE2C246Q38004963-F897FEA3-A33F-452D-8AD0-34CA1F1F73ECQ38085972-57DE2B09-83C8-46A3-9960-86B9471CD37BQ38165092-5CDEB101-E39F-46A1-9BDF-A0311198702B
P2860
Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Mechanism of glycosaminoglycan ...... er connective tissue diseases.
@ast
Mechanism of glycosaminoglycan ...... er connective tissue diseases.
@en
type
label
Mechanism of glycosaminoglycan ...... er connective tissue diseases.
@ast
Mechanism of glycosaminoglycan ...... er connective tissue diseases.
@en
prefLabel
Mechanism of glycosaminoglycan ...... er connective tissue diseases.
@ast
Mechanism of glycosaminoglycan ...... er connective tissue diseases.
@en
P2093
P2860
P1476
Mechanism of glycosaminoglycan ...... er connective tissue diseases.
@en
P2093
Calogera M Simonaro
Edward H Schuchman
Efrat Eliyahu
Marina D'Angelo
Mark E Haskins
Nataly Shtraizent
Xingxuan He
P2860
P304
P356
10.2353/AJPATH.2008.070564
P407
P577
2007-12-13T00:00:00Z